Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H14O6.2Na.H2O |
Molecular Weight | 450.3485 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Na+].[Na+].OC1=C(CC2=C3C=CC=CC3=CC(C([O-])=O)=C2O)C4=C(C=CC=C4)C=C1C([O-])=O
InChI
InChIKey=DNQSGXVJKQBSMT-UHFFFAOYSA-L
InChI=1S/C23H16O6.2Na.H2O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;;;/h1-10,24-25H,11H2,(H,26,27)(H,28,29);;;1H2/q;2*+1;/p-2
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C23H15O6 |
Molecular Weight | 387.3616 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20826425Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27064272 | https://www.ncbi.nlm.nih.gov/pubmed/20580560
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27064272 | https://www.ncbi.nlm.nih.gov/pubmed/20580560
Pamoic acid, also called embonic acid, is a naphthoic acid derivative, used as a counter ion of a drug compound to increase the solubility of the drug in water. Pamoic acid has agonist activity for the orphan G protein-coupled receptor GPR35 by which it activates ERK and beta-arrestin2, and causes antinociceptive activity. Although (like other drug salts) it has been considered an inactive compound by the FDA.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1293267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425 |
79.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. | 2001 |
|
Pharmacokinetic disposition and faecal excretion of pyrantel embonate following oral administration in horses. | 2001 Feb |
|
Voltage activated calcium channels in somatic muscle of filarial nematode Setaria cervi. | 2001 Jun |
|
Resistance against migrating ascaris suum larvae in pigs immunized with infective eggs or adult worm antigens. | 2001 Jun |
|
Ziprasidone and migraine headache. | 2002 Aug |
|
Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. | 2002 Jul 15 |
|
Comparison of the structures of natural and re-established populations of Ascaris in humans in a rural community of Jiangxi, China. | 2002 Jun |
|
Strongyloides stercoralis infection with bloody pericardial effusion in a non-immunosuppressed patient. | 2002 Jun |
|
Synergistic effects of pyrantel and the febantel metabolite fenbendazole on adult Toxocara canis. | 2003 Jul |
|
Common intestinal parasites. | 2004 Mar 1 |
|
Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. | 2005 Jan 13 |
|
Target animal safety and tolerance study of pyrantel pamoate paste (19.13% w/w pyrantel base) administered orally to horses. | 2005 Winter |
|
Heart failure caused by hookworm infection possibly associated with organic food consumption. | 2006 |
|
Field studies on endoparasites of Thoroughbred foals on seven farms in central Kentucky in 2004. | 2006 Apr |
|
Clinical field efficacy and safety of pyrantel pamoate paste (19.13% w/w pyrantel base) against Anoplocephala spp. in naturally infected horses. | 2006 Apr 15 |
|
Strongyle egg shedding consistency in horses on farms using selective therapy in Denmark. | 2006 Feb 18 |
|
[A case of drug eruption induced by hydroxyzine pamoate]. | 2006 Jan |
|
Determination of antihelminthic drug pyrantel pamoate in bulk and pharmaceutical formulations using electro-analytical methods. | 2006 Sep 15 |
|
Comparison of various anthelmintic therapies for the treatment of Trypanoxyuris microon infection in owl monkeys (Aotus nancymae). | 2007 Apr |
|
Occurrence of anthelmintic resistant equine cyathostome populations in central and southern Italy. | 2007 Dec 14 |
|
Revalidation and rationale for high pKa values of unconjugated bilirubin. | 2007 May 2 |
|
Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. | 2008 |
|
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. | 2008 |
|
Anthelmintic prescribing patterns of a sample of general practitioners from selected areas in the colombo district of sri lanka. | 2008 Apr |
|
Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy. | 2008 Mar 26 |
|
Education and imaging. Gastrointestinal: ascariasis. | 2008 Nov |
|
Gateways to clinical trials. | 2008 Oct |
|
Influence of Bi 58 Nowy (38% dimethoate) on pyrantel embonate concentration in the liver of rats. | 2009 |
|
Field effectiveness of pyrantel and failure of Parascaris equorum egg count reduction following ivermectin treatment in Italian horse farms. | 2009 Apr 6 |
|
Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. | 2009 Jan |
|
Second-generation antipsychotic long-acting injections: systematic review. | 2009 Nov |
|
Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. | 2009 Nov 29 |
|
Diagnosis and control of anthelmintic-resistant Parascaris equorum. | 2009 Sep 25 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
Abdominal Constriction Test in Mice were used for Pamoic acid activity evaluation. Four groups of 10 male, Swiss-Webster mice (30–35 g; Ace Animals, Inc., Boyertown, PA) were used. They were then injected with saline or one of three doses of pamoic acid disodium (25, 50, and 100 mg/kg s.c.). Twenty minutes later, each mouse was challenged with 0.6% acetic acid (0.30 ml/30 g animal i.p.) and, after an additional 5 min, was observed over the subsequent 10 min for abdominal writhing behavior.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
U2OS cells transiently expressing human GPR35b and _arr2-GFP or HEK 293 cells transiently expressing mouse GPR35 and beta arr2-GFP were used 48 h after transfection. U2OS cells permanently expressing HA-GPR35a and _arr2-GFP (UGPR35_) were used for most experiments. Cells were plated onto coverslips, placed in 24-well plates, and pretreated for 1 h with 0.02 mg/ml poly-Dlysine. Cells were maintained at 37°C in 5% CO2 until ready for experiments (80–85% confluent) and washed once with HBSS before drug application and experiments were performed in HBSS. Agonist stimulated redistribution of _arr2-GFP was assessed after drug treatment for 40 min. Experiments involving antagonist were done with 15 min preincubation of antagonist for both the stable UGPR35 cells and the transiently transfected mouse GPR35 HEK293 cells. To examine reversibility of the antagonist, cells were preincubated with 100 nM CID2745687 for 10 min, then washed with HBSS five times for 5 min each before adding 1 mkM pamoic acid. Cells were then fixed with 4% paraformaldehyde for 20 min at room temperature followed by three washes with HBSS.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:27:10 GMT 2023
by
admin
on
Sat Dec 16 09:27:10 GMT 2023
|
Record UNII |
ZL7OV5621O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7043796
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
PRIMARY | |||
|
2386241
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
PRIMARY | |||
|
100000133640
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
PRIMARY | |||
|
71607-30-2
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
PRIMARY | |||
|
54678147
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
PRIMARY | |||
|
ZL7OV5621O
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
PRIMARY | |||
|
SUB52833
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
PRIMARY | |||
|
207605-38-7
Created by
admin on Sat Dec 16 09:27:10 GMT 2023 , Edited by admin on Sat Dec 16 09:27:10 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY |